Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. — San Antonio, Texas

Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. is a clinical research site located in San Antonio, Texas, United States 78229.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. has participated in 1 clinical trials.

Therapeutic areas: Hematologic Malignancies, AML.

Sponsors: Clavis Pharma.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd.?

Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. conducted?

Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. has 1 clinical trials on record. Their work covers Hematologic Malignancies, AML.

Is Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. accredited by Crixeo Health?

Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd.?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.